Bristol Myers goes direct-to-consumer on one of its blockbuster drugs. Here's our take

The S&P 500 advanced, supported by technology and industrials. Amazon's AWS job cuts signal a strategic focus on efficiency and margin improvement, potentially leveraging AI to reduce operating expenses. Concurrently, Bristol Myers Squibb and Pfizer announced a direct-to-consumer program for Eliquis, offering a 40% discount; this move is expected to circumvent pharmacy benefit managers without a significant net pricing headwind, given existing rebates, and may garner political favor amidst drug pricing reform discussions. Investors are also anticipating upcoming earnings from major companies like American Express and Netflix, alongside key economic data.

Analysis

The market is exhibiting sector-specific strength, with technology and industrials lifting the S&P 500. Amazon's job cuts within its AWS division are not viewed as a signal of weakening demand but rather a strategic effort to improve efficiency and support margins, potentially accelerated by AI adoption which is reducing operating expenses as a percentage of sales for large tech firms. In the pharmaceutical sector, Bristol Myers Squibb and Pfizer are proactively managing pricing pressures and the PBM landscape by launching a direct-to-consumer program for Eliquis, a key drug generating approximately $14.3 billion for BMY. Analysts suggest this 40% discount to the list price will not create a net pricing headwind due to the circumvention of existing PBM rebates. Despite this strategic move, the investment thesis for Bristol Myers remains contingent on a critical, high-risk catalyst: the upcoming Phase 3 data for Cobenfy in late Q3 or early Q4, which is considered a make-or-break event for the stock following a previous trial disappointment.

Key Decisions for Investors

• View Amazon's workforce reduction in AWS as a positive indicator of operational discipline and a potential driver for margin expansion, not as a sign of deteriorating cloud demand.
• For Bristol Myers Squibb, the Eliquis direct-to-consumer initiative is a neutral-to-positive development, but positions should be managed with extreme caution ahead of the binary outcome from the upcoming Cobenfy Phase 3 trial data.
• Pay close attention to upcoming earnings from American Express and 3M, as their results will serve as crucial read-throughs for consumer credit health via Capital One and for industrial sector activity via DuPont and Honeywell.